Navigation Links
CSafe Signs Master Lease With Cathay Pacific Airways to Further Enhance Healthcare and Pharmaceutical Transport
Date:6/16/2010

DAYTON, Ohio, June 16 /PRNewswire/ -- CSafe, LLC, www.csafellc.com, manufacturer of the AcuTemp® RKN active temperature controlled cargo container, and Cathay Pacific, www.cathaypacific.com, one of the world's top ten international providers of air cargo services, have signed a master lease agreement for CSafe's active temperature controlled containers.

The agreement enhances the product offerings provided by Cathay Pacific's PHARMA LIFT service in meeting the needs of healthcare and pharmaceutical customers that require strict temperature control of their products during transport.  The FAA and EASA approved AcuTemp RKN offers the superior performance needed for shipping products with temperature requirements between +4 degrees Celsius to + 25 degrees Celsius.

"We have had much success with the use of the AcuTemp RKN and with it, have been able to offer our customers satisfied performance benefits of the unit," said Jack Lo, Cargo Product and Marketing Manager of Cathay Pacific.  "The heating and cooling capability of this unit, plus its ability to operate in extreme ambient conditions without the use of dry ice has been a welcome addition to our worldwide PHARMA LIFT product offering," he said.

"Cathay Pacific offers their customers a strong global network of wide body aircraft and shipping lanes, and we are extremely pleased to have them as a CSafe airline partner," stated Brian Kohr, General Manager of CSafe.  "Their success with our unit has shown that they are very qualified to handle the most important temperature controlled products," he added.

The superior performance of the CSafe AcuTemp RKN can be attributed to the thermal capabilities of ThermoCor® insulation which provides extended operating efficiencies as well as the unit's proprietary air movement, heating, and cooling systems that allow the AcuTemp RKN to maintain a consistent user-selected payload set-point across ambient temperatures as extreme as -30 degrees C up to +49 degrees C. The operating efficiency of the unit allows for a full load of product inside the container without the need for secondary packaging.  This makes the AcuTemp RKN a cost effective solution compared to dry ice and other passive solutions.  


'/>"/>
SOURCE CSafe, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcuTemp Thermal Systems and CSafe, LLC to Offer Temperature Controlled Containers to Aid in Relief Efforts in Haiti
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
6. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
7. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
8. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
9. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
10. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
11. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2015 through 2022. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/24/2017)... , Feb. 23, 2017  This report analyzes ... by the following Products: Intermediates, Analytical, ... the report include Pharmaceuticals, and Agrochemicals. The report provides ... , Europe , and Rest ... the period 2015 through 2022. Also, a six-year historic ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... tooth replacement options at his office, Antoine Dental Center. Currently, patients can get ... Some restrictions may apply, but patients can learn more about these offers by ...
(Date:2/24/2017)... ... , ... An in-depth computational analysis of genetic variants implicated in both schizophrenia ... that may explain why susceptibility to one of the disorders could place individuals at ... in the journal npj Schizophrenia. , “There is a wealth of genomic data ...
(Date:2/24/2017)... NY (PRWEB) , ... February 24, 2017 , ... In ... needs to be a top priority because it’s not if you will be attacked, ... safety, especially when it comes to digital health care. , Improvements in auditing and ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
Breaking Medicine News(10 mins):